14 Oktober 2024
16 Januari 2023
20 Oktober 2022
| Sinovac* | Inactivated Virus | 2 (0.5 ml perdoses) | 28 hari | Intramuskular |
| AstraZeneca* | Viral Vector (non-replicating) | 2 (0.5 ml perdoses) | 12 minggu | Intramuskular |
| Sinopharm* | Inactivated Virus | 2 (0.5 ml perdoses) | 21 hari | Intramuskular |
| Moderna* | mRNA/RNA-based | 2 (0.5 ml perdoses) | 28 hari | Intramuskular |
| Pfizer | RNA-based | 2 (0.5 ml perdoses) | 21-28 hari | Intramuskular |
| Novavax | Protein Sub-unit | 2 (0.5 ml perdoses) | 21 hari | Intramuskular |
| 1 | Tenaga Kesehatan | 2,080 | 2,049 | 98.51 % | 1,966 | 94.52 % |
| 2 | Petugas Pelayan Publik | 19,275 | 24,323 | 126.19 % | 20,906 | 108.46 % |
| 3 | Lansia (60 Tahun Keatas) | 16,755 | 11,247 | 67.13 % | 7,368 | 43.97 % |
| 4 | Masyarakat Rentan (50-60 Tahun) | 22,896 | 12,978 | 56.68 % | 5,394 | 23.56 % |
| 5 | Remaja (12-17 Tahun) | 39,412 | 18,034 | 45.76 % | 6,791 | 17.23 % |
| 6 | Masyarakat Umum (18-49) | 102,409 | 66,790 | 65.22 % | 17,505 | 17.09 % |
| 7 | Proyeksi Tambahan Sasaran | 47,173 | 0 | 0.00 % | 0 | 0.00 % |
| TOTAL | ||||||
Bagaimana Menurut Pendapat Anda tentang Website ini?
.jpeg)
.jpeg)
.jpg)
